Research programme: vitronectin receptor antagonists - Uriach

Drug Profile

Research programme: vitronectin receptor antagonists - Uriach

Alternative Names: Vitronectin receptor antagonists research programme - Uriach

Latest Information Update: 20 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Uriach
  • Class
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis; Osteoporosis; Vascular restenosis

Most Recent Events

  • 20 Jan 2004 Discontinued - Preclinical for Cancer in Spain (unspecified route)
  • 20 Jan 2004 Discontinued - Preclinical for Coronary artery restenosis in Spain (unspecified route)
  • 20 Jan 2004 Discontinued - Preclinical for Osteoporosis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top